芪参二莲汤联合恩替卡韦治疗乙型肝炎肝纤维化临床研究
发布时间：2019-04-03 07:04
【摘要】：目的观察芪参二莲汤联合恩替卡韦片治疗乙型肝炎肝纤维化的临床疗效。方法将74例乙型肝炎肝纤维化患者随机分为治疗组38例和对照组36例。对照组给予恩替卡韦片,治疗组在对照组治疗基础上加用芪参二莲汤。48周为1个疗程,治疗结束后继续给予恩替卡韦片,并随访24周。比较2组患者治疗前后肝功能、HBV-DNA、血清转化生长因子-β1(TGF-β1)、骨形态发生蛋白7(BMP-7)、肝纤维化指标及临床症状的变化。结果治疗组剔除3例、失访3例,对照组失访6例。治疗组治疗12、24、36、48周及随访24周时肝功能指标、HBV-DNA均较治疗前明显下降(P0.01),且均明显优于对照组(P0.01)。与治疗前比较,2组治疗后TGF-β1均下降(P0.05),BMP-7均升高(P0.01),TGF-β1/BMP-7比值均下降(P0.01),组间比较差异有统计学意义(P0.05)。治疗组治疗后及随访时透明质酸、层黏连蛋白、Ⅲ型前胶原、Ⅳ型胶原、肝脏弹性成像较治疗前明显下降(P0.01),与对照组比较差异有统计学意义(P0.01)。治疗组治疗后及随访时乏力、肝区不适、恶心厌油及纳差均明显好转,与对照组比较差异有统计学意义(P0.05)。结论芪参二莲汤联合恩替卡韦片具有良好的保肝降酶、抗病毒及逆转肝纤维化的作用。
[Abstract]:Objective to observe the clinical effect of Qishen Erlian decoction combined with enecavir tablet in treatment of hepatitis B liver fibrosis. Methods 74 patients with hepatitis B liver fibrosis were randomly divided into treatment group (38 cases) and control group (36 cases). The treatment group was treated with Qishen Erlian decoction on the basis of the control group. 48 weeks was a course of treatment. After the treatment, the patients were given ntekavel tablets and followed up for 24 weeks. The changes of liver function, HBV-DNA, serum transforming growth factor-尾 1 (TGF- 尾 1), bone morphogenetic protein 7 (BMP-7), hepatic fibrosis indexes and clinical symptoms were compared between the two groups before and after treatment. Results in the treatment group, 3 cases were excluded, 3 cases lost follow-up, and 6 cases in the control group. After 12, 24, 36, 48 weeks and 24 weeks of follow-up, the liver function indexes and HBV-DNA in the treatment group were significantly lower than those before treatment (P0.01), and were significantly better than those in the control group (P0.01). Compared with pre-treatment, TGF- 尾 1 decreased (P0.05), BMP-7 increased (P0.01), TGF- 尾 1 / BMP-7 ratio decreased (P0.01), the difference between the two groups was statistically significant (P0.05). Hyaluronic acid, laminin, type 鈪，
本文编号：2453007
[Abstract]:Objective to observe the clinical effect of Qishen Erlian decoction combined with enecavir tablet in treatment of hepatitis B liver fibrosis. Methods 74 patients with hepatitis B liver fibrosis were randomly divided into treatment group (38 cases) and control group (36 cases). The treatment group was treated with Qishen Erlian decoction on the basis of the control group. 48 weeks was a course of treatment. After the treatment, the patients were given ntekavel tablets and followed up for 24 weeks. The changes of liver function, HBV-DNA, serum transforming growth factor-尾 1 (TGF- 尾 1), bone morphogenetic protein 7 (BMP-7), hepatic fibrosis indexes and clinical symptoms were compared between the two groups before and after treatment. Results in the treatment group, 3 cases were excluded, 3 cases lost follow-up, and 6 cases in the control group. After 12, 24, 36, 48 weeks and 24 weeks of follow-up, the liver function indexes and HBV-DNA in the treatment group were significantly lower than those before treatment (P0.01), and were significantly better than those in the control group (P0.01). Compared with pre-treatment, TGF- 尾 1 decreased (P0.05), BMP-7 increased (P0.01), TGF- 尾 1 / BMP-7 ratio decreased (P0.01), the difference between the two groups was statistically significant (P0.05). Hyaluronic acid, laminin, type 鈪，
本文编号：2453007
本文链接：https://www.wllwen.com/yixuelunwen/chuanranbingxuelunwen/2453007.html
最近更新
教材专著
